

Section I – Dispensing Pharmacy Information

Pharmacy Name	Phone	Fax
----------------------	--------------	------------

Section II – Patient Demographics

Name	Medicaid ID	Date of Birth	Gestational Age _____ weeks and ____/7th day
Address			County of residence

Has patient received a Synagis prophylactic injection during hospitalization since the start of the current RSV season?

No Yes If yes, number of shots: _____ Dose (mg): _____ Date: _____

Section III – Patient Diagnosis

<input type="checkbox"/> Patients who are younger than 24 months chronological age at the start of the RSV season can qualify, for up to 5 monthly doses of Synagis, based on the criteria listed to the right. Diagnoses and conditions must be clearly documented in the client’s medical record. *Refer to page 2 for definition.	<input type="checkbox"/> 24-1: Active diagnosis of chronic lung disease (CLD) of prematurity* AND required any of the following therapies within the 6 months prior to the current RSV season (check all that apply): ICD-9-CM code: <input type="checkbox"/> Chronic systemic corticosteroids <input type="checkbox"/> Diuretics <input type="checkbox"/> 21% Supplemental oxygen <input type="checkbox"/> Long-Term Mechanical Ventilator <input type="checkbox"/> Bronchodilator therapy
	<input type="checkbox"/> 24-2: Profoundly immunocompromised during the RSV season (solid organ or hematopoietic stem cell transplant, chemotherapy or other condition that leaves the infant profoundly immunocompromised): ICD-9-CM code:
<input type="checkbox"/> Patients who are younger than 12 months chronological age at the start of the RSV season can qualify, for up to 5 monthly doses of Synagis, based on criteria listed to the right.	<input type="checkbox"/> 12-1: ≤ 28 6/7 weeks gestational age at birth: ICD-9-CM code:
	<input type="checkbox"/> 12-2: Chronic lung disease (CLD) of prematurity: ICD-9-CM code:
	<input type="checkbox"/> 12-3: Severe congenital abnormality of airway OR severe neuromuscular disease that impairs the ability to clear secretions from the upper airway because of ineffective cough: ICD-9-CM code:
<input type="checkbox"/> Patients who are younger than 6 months chronological age at the start of the RSV season can qualify, for up to 5 monthly doses of Synagis, based on criteria to the right.	<input type="checkbox"/> 12-4: Active diagnosis of hemodynamically significant heart disease: ICD-9-CM code: AND <input type="checkbox"/> CHF on medication OR <input type="checkbox"/> Moderate to severe Pulmonary Hypertension OR <input type="checkbox"/> Cyanotic heart disease (in consultation with a pediatric cardiologist) (NOTE: This excludes infants with hemodynamically insignificant heart disease - refer to page 2 for list)
	<input type="checkbox"/> 6-1: < 31 6/7 weeks gestational age at birth: ICD-9-CM code:

Section IV – Other Condition(s)

Synagis is prescribed by or in consultation with an appropriate Pediatric Subspecialist † for a patient younger than 24 months of age with any of the conditions in Section VII. († Refer to page 2 for a list of appropriate Pediatric Subspecialties and conditions.)

Subspecialist: _____ Subspecialty: _____ Date: _____

Important note: Monthly prophylaxis should be discontinued in any child who experiences a breakthrough RSV hospitalization.

Section V – Synagis Prescription (to be completed by prescriber)

Rx: Synagis (palivizumab) Liquid Solution vial	Quantity: _____	Dose (mg): _____	Refills: _____
Sig: Inject 15mg/kg one time per month	Current Weight: _____ (kg) or (lbs.)		
<input type="checkbox"/> Syringes 1ml 25G 5/8” <input type="checkbox"/> Syringes 3ml 20G 1”	<input type="checkbox"/> Epinephrine 1:1000 amp. Sig: Inject 0.01mg/kg as directed.		
Prescriber Name	Date	Phone	Fax
Address, City, State & ZIP			NPI
Physician Signature:			License number:

Section VI.

Category	Subcategories
Chronic Lung Disease (CLD) of Prematurity *	Born < 32 week, 0 day gestational age who require >21% oxygen for at least 28 days after birth.
Pediatric Subspecialist ‡	<ul style="list-style-type: none"> • Neonatologist • Pediatric Intensivist • Pediatric Pulmonologist • Pediatric Cardiologist • Pediatric Infectious Disease Subspecialist
Hemodynamically significant heart disease	<ul style="list-style-type: none"> • Congestive heart failure (CHF) requiring medication • Moderate to severe pulmonary hypertension • Unrepaired cyanotic congenital heart disease
The following groups of infants are NOT AT INCREASED risk of RSV and generally should not receive immunoprophylaxis:	
1. Hemodynamically <i>insignificant</i> heart disease	<ul style="list-style-type: none"> • Secundum atrial septal defect • Small ventriculoseptal defect • Pulmonic stenosis • Uncomplicated aortic stenosis • Mild coarctation of the aorta • Patent ductus arteriosus
2. Congenital heart disease adequately corrected by surgery which does not continue to require medication for congestive heart failure	
3. Mild cardiomyopathy that does not require medical therapy for the condition	
Note: Tobacco smoke exposure is <u>not</u> an indication for Synagis administration. Tobacco dependent parents should be offered tobacco dependence treatment or referral for tobacco dependence treatment. 1-877-YES-QUIT (1-877-937-7848, YesQuit.org) is the Quitline operated in Texas.	

Section VII.

Clinical prior authorization staff will give additional consideration for approval of prior authorization requests for infants and children younger than 24 months that do not meet criteria in Section III of the request form if the patient meets one or more of the following conditions and the prescription was written by or in consultation with a pediatric sub-specialist:

- * Children in the second year of life because a mean decrease in palivizumab serum concentration of 58% was observed after surgical procedures that involve cardiopulmonary bypass, for children who are receiving prophylaxis and who continue to require prophylaxis after a surgical procedure, a post-operative dose of palivizumab (15mg/kg) should be considered after cardiac bypass or at the conclusion of extra-corporeal membrane oxygenation for infants and children younger than 24 months.
- * Infants and children that have undergone chemotherapy, hematopoietic stem cell transplantation, or solid organ transplant.
- * In some cases in children with Down syndrome plus a condition that may increase the risk of respiratory syncytial virus (RSV) infection.
- * Cystic Fibrosis plus other conditions such as clinical evidence of chronic lung disease (CLD) and nutritional compromise in the first year of life, as defined on page 1 of the request form.
- * Cystic Fibrosis plus severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persist when stable) or weight for length less than the tenth percentile in second year of life.